• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CenterWatch Monthly December 2008

CenterWatch Monthly December 2008

December 5, 2008
CenterWatch Staff

Demand for Medical Writing Continues to Rise

According to CenterWatch analysis, the medical writing market has more than doubled in size during the past five years, increasing from an estimated $345 million in 2003 to $694 million in 2008.

Making the Business Case for Accreditation

When the Association for the Accreditation of Human Research Protection Programs (AAHRPP) launched in 2001, its first accredited organizations comprised a few market segments. Today, AAHRPP has accredited 138 parent organizations, representing more than 600 entities from almost every type of human research organization.

Conditional and Accelerated Approach No Easy Route to Market Success

The accelerated and conditional approval processes are coming under close scrutiny in Europe, raising the possibility of a shake-up in how priority drugs are regulated over the coming months. One casualty could be the randomized clinical trial’s position as the “gold standard” of evidence in assessing drug efficacy.

Eye On: Juvenile Arthritis

Juvenile arthritis (JA), which is any type of arthritis or arthritis-related condition in young people under 18 years of age, affects approximately 294,000 children in the United States, according to the Arthritis Foundation. Typical symptoms are joint pain, swelling, tenderness and stiffness, which must be confirmed by physical examination. Ultimately, JA may progress to cause restricted range of motion, contracture, damage, deformity and/or altered growth of affected joints.

To read the full articles for this issue or for more information on these and other breaking stories, pleaseclick here

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing